196 related articles for article (PubMed ID: 38456406)
21. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
[TBL] [Abstract][Full Text] [Related]
22. [Contemporary epidemiology and treatment of hospitalized heart failure patients in real clinical practice in China].
Wang H; Li YY; Chai K; Zhang W; Li XL; Dong YG; Zhou JM; Huo Y; Yang JF
Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):865-874. PubMed ID: 31744275
[No Abstract] [Full Text] [Related]
23. Atrial fibrillation and risk of adverse outcomes in heart failure with reduced, mildly reduced, and preserved ejection fraction: A systematic review and meta-analysis.
Kroshian G; Joseph J; Kinlay S; Peralta AO; Hoffmeister PS; Singh JP; Yuyun MF
J Cardiovasc Electrophysiol; 2024 Apr; 35(4):715-726. PubMed ID: 38348517
[TBL] [Abstract][Full Text] [Related]
24. Atrial Fibrillation in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction.
Sartipy U; Dahlström U; Fu M; Lund LH
JACC Heart Fail; 2017 Aug; 5(8):565-574. PubMed ID: 28711451
[TBL] [Abstract][Full Text] [Related]
25. ADDition of DAPAgliflozin, Sodium-Glucose Cotransporter-2 Inhibitor to Angiotensin Receptor Blocker-Neprilysin Inhibitors Non-Responders in Patient with Refractory Heart Failure with Reduced Ejection Fraction (ADD DAPA trial).
Jariwala P; Jadhav K; Punjani A; Boorugu H; Mari AR
Indian Heart J; 2021; 73(5):605-611. PubMed ID: 34627577
[TBL] [Abstract][Full Text] [Related]
26. Angiotensin Receptor Neprilysin Inhibitor for Patients With Heart Failure and Reduced Ejection Fraction: Real-World Experience From Taiwan.
Hsiao FC; Wang CL; Chang PC; Lu YY; Huang CY; Chu PH
J Cardiovasc Pharmacol Ther; 2020 Mar; 25(2):152-157. PubMed ID: 31514513
[TBL] [Abstract][Full Text] [Related]
27. Outcomes of incident atrial fibrillation in heart failure with preserved or reduced ejection fraction: A community-based study.
Zhang P; Chamberlain AM; Hodge DO; Cai C; Xiao PL; Han J; Jiang CY; Redfield MM; Roger VL; Cha YM
J Cardiovasc Electrophysiol; 2020 Sep; 31(9):2275-2283. PubMed ID: 32584498
[TBL] [Abstract][Full Text] [Related]
28. Atrial fibrillation and risk of progressive heart failure in patients with preserved ejection fraction heart failure.
Gierula J; Cole CA; Drozd M; Lowry JE; Straw S; Slater TA; Paton MF; Byrom RJ; Garland E; Halliday G; Winsor S; Lyall GK; Birch K; McGinlay M; Sunley E; Grant PJ; Wessels DH; Ketiar EM; Witte KK; Cubbon RM; Kearney MT
ESC Heart Fail; 2022 Oct; 9(5):3254-3263. PubMed ID: 35790085
[TBL] [Abstract][Full Text] [Related]
29. Atrial fibrillation and risk of incident heart failure with reduced versus preserved ejection fraction.
Nicoli CD; O'Neal WT; Levitan EB; Singleton MJ; Judd SE; Howard G; Safford MM; Soliman EZ
Heart; 2022 Mar; 108(5):353-359. PubMed ID: 34031160
[TBL] [Abstract][Full Text] [Related]
30. Real-world use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure Registry.
Stolfo D; Lund LH; Benson L; Lindberg F; Ferrannini G; Dahlström U; Sinagra G; Rosano GMC; Savarese G
Eur J Heart Fail; 2023 Sep; 25(9):1648-1658. PubMed ID: 37419495
[TBL] [Abstract][Full Text] [Related]
31. Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities.
Albert NM; Tyson RJ; Hill CL; DeVore AD; Spertus JA; Duffy C; Butler J; Patterson JH; Hernandez AF; Williams FB; Thomas L; Fonarow GC
Am Heart J; 2021 May; 235():82-96. PubMed ID: 33497697
[TBL] [Abstract][Full Text] [Related]
32. Advance in the pharmacological and comorbidities management of heart failure with preserved ejection fraction: evidence from clinical trials.
Meifang W; Ying W; Wen C; Kaizu X; Meiyan S; Liming L
Heart Fail Rev; 2024 Mar; 29(2):305-320. PubMed ID: 37561223
[TBL] [Abstract][Full Text] [Related]
33. Shift of conventional paradigm of heart failure treatment: from angiotensin receptor neprilysin inhibitor to sodium-glucose co-transporter 2 inhibitors?
Berezin AE; Berezin AA
Future Cardiol; 2021 May; 17(3):497-506. PubMed ID: 33615880
[TBL] [Abstract][Full Text] [Related]
34. Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review.
Mentz RJ; Brunton SA; Rangaswami J
Cardiovasc Diabetol; 2023 Nov; 22(1):316. PubMed ID: 37974185
[TBL] [Abstract][Full Text] [Related]
35. Clinical outcomes in heart failure patients with and without atrial fibrillation receiving sodium-glucose cotransporter-2 inhibitor.
Hu WS; Lin CL
Naunyn Schmiedebergs Arch Pharmacol; 2023 Sep; 396(9):1977-1986. PubMed ID: 36881169
[TBL] [Abstract][Full Text] [Related]
36. Association between sodium-glucose cotransporter-2 inhibitors and incident atrial fibrillation/atrial flutter in heart failure patients with reduced ejection fraction: a meta-analysis of randomized controlled trials.
Sfairopoulos D; Liu T; Zhang N; Tse G; Bazoukis G; Letsas K; Goudis C; Milionis H; Vrettos A; Korantzopoulos P
Heart Fail Rev; 2023 Jul; 28(4):925-936. PubMed ID: 36282460
[TBL] [Abstract][Full Text] [Related]
37. Atrial resynchronization therapy in patients with atrial fibrillation and heart failure with and without systolic left ventricular dysfunction: a pilot study.
Saksena S; Slee A; Saad M
J Interv Card Electrophysiol; 2018 Oct; 53(1):9-17. PubMed ID: 29987682
[TBL] [Abstract][Full Text] [Related]
38. Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction.
Gonzalez J; Bates BA; Setoguchi S; Gerhard T; Dave CV
Cardiovasc Diabetol; 2023 Mar; 22(1):54. PubMed ID: 36899387
[TBL] [Abstract][Full Text] [Related]
39. Combined effects of ARNI and SGLT2 inhibitors in diabetic patients with heart failure with reduced ejection fraction.
Kim HM; Hwang IC; Choi W; Yoon YE; Cho GY
Sci Rep; 2021 Nov; 11(1):22342. PubMed ID: 34785723
[TBL] [Abstract][Full Text] [Related]
40. Real-World Experience of Angiotensin Receptor-Neprilysin Inhibition in Reduced Ejection Fraction Heart Failure Patients With Advanced Kidney Disease.
Chang HY; Lin CC; Chao CJ; Lin YC; Wang YC; Liao CT; Huang JL; Lee YH; Huang CY; Chien LN; Hsu CY
Mayo Clin Proc; 2023 Jan; 98(1):88-99. PubMed ID: 36109207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
